

**Experiment Number:** 20209 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS  
ABRIDGED) (a)**

**Date Report Requested:** 08/14/2014

**Test Type:** CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

**Time Report Requested:** 07:47:55

**Route:** GAVAGE

**CAS Number:** 32534-81-9

**First Dose M/F:** 02/25/08 / 02/25/08

**Species/Strain:** MICE/B6C3F1

**Lab:** SRI

F1\_M3

**NTP Study Number:** C20209  
**Lock Date:** 08/31/2011  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 3.0.2.1\_001  
**PWG Approval Date:** NONE

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

## Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Dosing Accident	1			2
Moribund Sacrifice	15	7	14	36
Natural Death	5	10	5	12
Survivors				
Terminal Sacrifice	29	33	31	
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(43)	(42)	(41)	(31)
Intestine Large, Cecum	(46)	(43)	(45)	(45)
Intestine Large, Colon	(48)	(44)	(46)	(46)
Intestine Large, Rectum	(48)	(46)	(46)	(46)
Intestine Small, Duodenum	(46)	(43)	(47)	(44)
Intestine Small, Ileum	(45)	(41)	(44)	(43)
Intestine Small, Jejunum	(46)	(42)	(44)	(46)
Adenoma				1 (2%)
Carcinoma				1 (2%)
Liver	(50)	(50)	(50)	(50)
Hepatoblastoma	1 (2%)	1 (2%)	12 (24%)	5 (10%)
Hepatoblastoma, Multiple			4 (8%)	
Hepatocellular Adenoma	13 (26%)	12 (24%)	4 (8%)	7 (14%)
Hepatocellular Adenoma, Multiple	10 (20%)	23 (46%)	45 (90%)	33 (66%)
Hepatocellular Carcinoma	14 (28%)	13 (26%)	13 (26%)	10 (20%)
Hepatocellular Carcinoma, Multiple	4 (8%)	2 (4%)	17 (34%)	35 (70%)
Hepatocholangiocarcinoma		1 (2%)		
Mesentery	(12)	(3)	(9)	(5)
Hepatoblastoma, Metastatic, Liver			2 (22%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (8%)		1 (11%)	
Pancreas	(50)	(50)	(50)	(50)
Salivary Glands	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Carcinoma		1 (2%)		
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Papilloma	2 (4%)	1 (2%)	2 (4%)	3 (6%)
Stomach, Glandular	(50)	(48)	(48)	(50)
Tongue	(0)	(0)	(0)	(1)
Tooth	(2)	(1)	(0)	(1)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(48)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Capsule, Adenoma		1 (2%)	1 (2%)	
Adrenal Medulla	(50)	(50)	(50)	(48)
Pheochromocytoma Benign	1 (2%)			
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma	1 (2%)			
Parathyroid Gland	(48)	(43)	(49)	(44)
Adenoma		1 (2%)		
Pituitary Gland	(47)	(43)	(43)	(44)
Pars Distalis, Adenoma		1 (2%)		
Thyroid Gland	(50)	(49)	(50)	(49)
Follicular Cell, Adenoma	1 (2%)	1 (2%)	2 (4%)	

## GENERAL BODY SYSTEM

Tissue NOS	(2)	(1)	(0)	(1)
------------	-----	-----	-----	-----

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<b>GENITAL SYSTEM</b>				
Coagulating Gland	(1)	(0)	(1)	(0)
Hepatoblastoma, Metastatic, Liver			1 (100%)	
Epididymis	(50)	(50)	(50)	(50)
Granular Cell Tumor Benign			1 (2%)	
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Penis	(1)	(0)	(1)	(0)
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(49)	(49)
Testes	(50)	(50)	(50)	(49)
Interstitial Cell, Adenoma	1 (2%)		1 (2%)	
Rete Testes, Adenoma	1 (2%)			
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Cranium, Carcinoma, Metastatic, Zymbal'S Gland	1 (2%)			
Lymph Node	(5)	(4)	(4)	(1)
Fat, Hemangiosarcoma		1 (25%)		
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver		1 (25%)		
Thoracic, Hepatocholangiocarcinoma, Metastatic, Liver		1 (25%)		
Lymph Node, Mandibular	(50)	(49)	(49)	(46)
Lymph Node, Mesenteric	(49)	(47)	(46)	(47)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)		1 (2%)	
Spleen	(50)	(47)	(47)	(47)
Hemangiosarcoma	1 (2%)	1 (2%)		
Thymus	(40)	(41)	(40)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

## INTEGUMENTARY SYSTEM

Mammary Gland	(2)	(2)	(1)	(4)
Skin	(50)	(50)	(50)	(50)
Lipoma	1 (2%)			
Schwannoma Malignant			1 (2%)	
Lip, Mast Cell Tumor Benign			1 (2%)	
Subcutaneous Tissue, Lipoma	1 (2%)			

## MUSCULOSKELETAL SYSTEM

Bone	(49)	(50)	(50)	(49)
Skeletal Muscle	(2)	(2)	(0)	(0)
Hepatocolangiocarcinoma, Metastatic, Liver		1 (50%)		

## NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(2)	(1)	(1)	(0)
Spinal Cord	(1)	(1)	(1)	(0)

## RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	5 (10%)	4 (8%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple		2 (4%)		
Alveolar/Bronchiolar Carcinoma	4 (8%)	3 (6%)	1 (2%)	
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)	3 (6%)		
Carcinoma, Metastatic, Zymbal'S Gland	1 (2%)			
Hepatoblastoma, Metastatic, Liver			2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	6 (12%)	2 (4%)	4 (8%)	4 (8%)
Hepatocolangiocarcinoma, Metastatic, Liver		1 (2%)		
Nose	(50)	(48)	(50)	(50)
Pleura	(0)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Hepatocholangiocarcinoma, Metastatic, Liver		1 (100%)		
Trachea	(47)	(48)	(49)	(47)

## SPECIAL SENSES SYSTEM

Eye	(49)	(47)	(47)	(46)
Harderian Gland	(50)	(49)	(50)	(50)
Adenoma	5 (10%)	6 (12%)	3 (6%)	
Carcinoma	1 (2%)			
Zymbal's Gland	(1)	(0)	(0)	(0)
Carcinoma	1 (100%)			

## URINARY SYSTEM

Kidney	(50)	(50)	(49)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Renal Tubule, Adenoma		1 (2%)		
Renal Tubule, Carcinoma		1 (2%)	1 (2%)	
Urethra	(0)	(4)	(3)	(0)
Urinary Bladder	(50)	(49)	(48)	(48)
Hepatoblastoma, Metastatic, Liver			1 (2%)	

## SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)		
Lymphoma Malignant	5 (10%)	7 (14%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 20209 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Date Report Requested: 08/14/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

---

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
------------------	---------	---------	----------	-----------

---

**Tumor Summary for Males**

Total Animals with Primary Neoplasms (b)	40	46	49	48
Total Primary Neoplasms	75	89	113	96
Total Animals with Benign Neoplasms	30	39	49	41
Total Benign Neoplasms	42	53	63	45
Total Animals with Malignant Neoplasms	27	25	37	45
Total Malignant Neoplasms	33	36	50	51
Total Animals with Metastatic Neoplasms	7	3	7	4
Total Metastatic Neoplasms	11	9	13	4
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
--------------------	---------	---------	----------	-----------

**Disposition Summary**

<b>Animals Initially In Study</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>
<b>Early Deaths</b>				
<b>Accidentally Killed</b>	<b>1</b>			
<b>Dosing Accident</b>			<b>1</b>	
<b>Moribund Sacrifice</b>	<b>10</b>	<b>10</b>	<b>9</b>	<b>46</b>
<b>Natural Death</b>	<b>6</b>	<b>5</b>	<b>3</b>	<b>4</b>
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	<b>33</b>	<b>35</b>	<b>37</b>	
<b>Animals Examined Microscopically</b>	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Gallbladder	(44)	(44)	(47)	(45)
Intestine Large, Cecum	(46)	(45)	(47)	(47)
Intestine Large, Colon	(47)	(45)	(47)	(47)
Intestine Large, Rectum	(47)	(46)	(47)	(47)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Intestine Small, Duodenum	(46)	(45)	(47)	(47)
Intestine Small, Ileum	(46)	(45)	(47)	(47)
Intestine Small, Jejunum	(46)	(45)	(47)	(47)
Carcinoma			1 (2%)	
Liver	(50)	(49)	(50)	(49)
Hemangioma		1 (2%)		
Hemangiosarcoma			1 (2%)	
Hepatocellular Adenoma	5 (10%)	5 (10%)	11 (22%)	4 (8%)
Hepatocellular Adenoma, Multiple		2 (4%)	21 (42%)	42 (86%)
Hepatocellular Carcinoma	4 (8%)	1 (2%)	5 (10%)	19 (39%)
Hepatocellular Carcinoma, Multiple		1 (2%)	1 (2%)	8 (16%)
Serosa, Fibrosarcoma, Metastatic, Skin	1 (2%)			
Mesentery	(11)	(26)	(12)	(5)
Fibrosarcoma, Metastatic, Skin	1 (9%)			
Oral Mucosa	(0)	(1)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion



Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Pancreas	(50)	(48)	(50)	(50)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(48)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(49)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Squamous Cell Papilloma		3 (6%)	1 (2%)	2 (4%)
Stomach, Glandular	(49)	(47)	(47)	(48)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(47)	(49)	(50)	(49)
Heart	(50)	(50)	(50)	(49)

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(49)	(47)
Adenoma			1 (2%)	
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Capsule, Adenoma			1 (2%)	
Adrenal Medulla	(49)	(50)	(48)	(48)
Pheochromocytoma Benign			1 (2%)	
Pheochromocytoma Malignant				1 (2%)
Islets, Pancreatic	(50)	(48)	(50)	(50)
Adenoma	1 (2%)		2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Parathyroid Gland	(44)	(48)	(47)	(47)
Pituitary Gland	(50)	(47)	(46)	(45)
Pars Distalis, Adenoma	5 (10%)	5 (11%)	8 (17%)	
Pars Intermedia, Adenoma		2 (4%)		
Thyroid Gland	(50)	(49)	(48)	(47)
C-cell, Adenoma	1 (2%)			
Follicular Cell, Adenoma	1 (2%)			
Follicular Cell, Carcinoma		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
--------------------	---------	---------	----------	-----------

## GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
Tissue NOS	(1)	(2)	(0)	(1)

## GENITAL SYSTEM

Clitoral Gland	(49)	(49)	(50)	(50)
Ovary	(48)	(49)	(50)	(48)
Cystadenoma	2 (4%)	1 (2%)	3 (6%)	
Granulosa Cell Tumor Benign	1 (2%)			
Granulosa Cell Tumor Malignant				1 (2%)
Uterus	(50)	(50)	(50)	(49)
Adenoma	1 (2%)			
Hemangioma	1 (2%)			
Polyp Stromal		2 (4%)	3 (6%)	
Bilateral, Polyp Stromal			1 (2%)	
Vagina	(0)	(1)	(0)	(0)
Squamous Cell Carcinoma		1 (100%)		

## HEMATOPOIETIC SYSTEM

Bone Marrow	(49)	(50)	(50)	(49)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Lymph Node	(9)	(17)	(12)	(4)
Lymph Node, Mandibular	(48)	(50)	(50)	(45)
Lymph Node, Mesenteric	(48)	(45)	(49)	(48)
Spleen	(50)	(47)	(48)	(48)
Capsule, Fibrosarcoma, Metastatic, Skin	1 (2%)			
Thymus	(48)	(45)	(46)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(50)	(50)	(50)	(50)
Carcinoma	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Mast Cell Tumor Benign				1 (2%)
Lip, Mast Cell Tumor Benign				1 (2%)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)	1 (2%)		
Subcutaneous Tissue, Fibrous Histiocytoma, Multiple		1 (2%)		
Subcutaneous Tissue, Rhabdomyosarcoma, Metastatic, Skeletal Muscle			1 (2%)	
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(49)	(50)	(50)	(50)
Maxilla, Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Skeletal Muscle	(2)	(3)	(4)	(1)
Rhabdomyosarcoma	1 (50%)	2 (67%)	2 (50%)	
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(50)	(49)
Peripheral Nerve	(1)	(1)	(1)	(1)
Spinal Cord	(1)	(1)	(3)	(1)
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	5 (10%)	3 (6%)	
Alveolar/Bronchiolar Carcinoma		1 (2%)	1 (2%)	
Fibrosarcoma, Metastatic, Skin	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
Granulosa Cell Tumor Malignant, Metastatic, Ovary				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	2 (4%)	1 (2%)		1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin	1 (2%)			
Nose	(50)	(50)	(50)	(48)
Pleura	(0)	(0)	(1)	(0)
Trachea	(50)	(50)	(50)	(47)

## SPECIAL SENSES SYSTEM

Eye	(47)	(45)	(47)	(48)
Harderian Gland	(50)	(49)	(50)	(49)
Adenoma	9 (18%)	1 (2%)	4 (8%)	2 (4%)
Carcinoma	1 (2%)	1 (2%)	1 (2%)	

## URINARY SYSTEM

Kidney	(50)	(50)	(49)	(48)
Urinary Bladder	(49)	(50)	(49)	(48)

## SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	3 (6%)	1 (2%)	1 (2%)
Lymphoma Malignant	7 (14%)	6 (12%)	6 (12%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Experiment Number: 20209 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Date Report Requested: 08/14/2014

Test Type: CHRONIC

Pentabromodiphenyl oxide (technical) (DE 71)

Time Report Requested: 07:47:55

Route: GAVAGE

CAS Number: 32534-81-9

First Dose M/F: 02/25/08 / 02/25/08

Species/Strain: MICE/B6C3F1

Lab: SRI

---

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	30 MG/KG	100 MG/KG
--------------------	---------	---------	----------	-----------

---

**Tumor Summary for Females**

Total Animals with Primary Neoplasms (b)	34	30	41	49
Total Primary Neoplasms	44	46	79	83
Total Animals with Benign Neoplasms	24	20	38	46
Total Benign Neoplasms	28	27	60	52
Total Animals with Malignant Neoplasms	16	15	15	31
Total Malignant Neoplasms	16	19	19	31
Total Animals with Metastatic Neoplasms	4	1	1	3
Total Metastatic Neoplasms	13	1	3	3
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors